HIND
Vyome Holdings, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Vyome (HIND) Stock: Buy, Sell, or Hold?
$1.54
-0.05 (-3.14%)
▼
5d:
-12.99%
30d:
-23.38%
90d:
-30.63%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
39/100
Position
OVERSOLD
30-Day Fair Range
$1.67 – $1.97
Position: OVERSOLD
Forward P/E & Valuation
-1.9x
Next 12M consensus est.
Wall Street Target
$8.83
+473.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.53 / $2.14
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: HIND is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When HIND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: HIND is currently trading at $1.54, which is considered oversold relative to its 30-day fair value range of $1.67 to $1.97.
Technical Outlook: Technically, HIND is in a strong downtrend. The price is currently testing key support at $1.53. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: HIND scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.83 (+473.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HIND is in a strong downtrend. The price is currently testing key support at $1.53. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: HIND scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.83 (+473.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.67 -
$1.97
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
Trading Range & Key Levels
30-Day Trading Range
$1.67 -
$1.97
Current vs Trading Range
OVERSOLD
Support Level
$1.53
Resistance Level
$2.14
Current Trend
Strong Downtrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 473.6% below Wall St target ($8.83)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.93
Wall Street Target
$8.83
(+473.6%)
Revenue Growth (YoY)
-46.0%
Share HIND Analysis
Share this live HIND analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HIND)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jul 1, 2026
Daily AI digest
AI Retail Discussion Summary:
Vyome Holdings received a patent for its besifloxacin topical gel program for inflammatory acne in China, expanding its intellectual property protection and enhancing strategic optionality.
Key Retail Themes:
intellectual property
strategic optionality
China market
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:34 AM ET
Data refreshes hourly during market hours. Next update: 9:34 AM
Data refreshes hourly during market hours. Next update: 9:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 43 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 37 SELL |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 39 SELL |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$155 | 45 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HIND Research Pages